Jim Shrine

NIH Initiates Phase III Trial Of Avicena's Creatine Agent for PD

March 23, 2007

By Jim Shrine

NIH Initiates Phase III Trial Of Avicena's Creatine Agent for PD

March 23, 2007

By Jim Shrine

Avexa Raises $60.1M To Fund Phase III Trials Of HIV Agent

March 22, 2007

By Jim Shrine

Australian biotechnology company Avexa Ltd. parlayed positive Phase IIb data on its lead HIV compound into a funding round that will total A$75 million (US$60.1 million). (BioWorld Today)

Avexa Raises $60.1M To Fund Phase III Trials Of HIV Agent

March 22, 2007

By Jim Shrine

Australian biotechnology company Avexa Ltd. parlayed positive Phase IIb data on its lead HIV compound into a funding round that will total A$75 million (US$60.1 million). (BioWorld Today)